PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Result of a 1-year, prospective, randomized, placebo-controlled study

Marco Guazzi, Marco Vicenzi, Ross Arena, Maurizio D. Guazzi

Research output: Contribution to journalArticle

Abstract

Background-In heart failure (HF), a defective nitric oxide signaling is involved in left ventricular (LV) diastolic abnormalities and remodeling. PDE5 inhibition, by blocking degradation of nitric oxide second-messenger cyclic guanosine monophosphate, might be beneficial. In a cohort of systolic HF patients, we tested the effects of PDE5 inhibition (sildenafil) on LV ejection fraction, diastolic function, cardiac geometry, and clinical status. Methods and Results-Forty-five HF patients (New York Heart Association class II-III) were randomly assigned to placebo or sildenafil (50 mg three times per day) for 1 year, with assessment (6 months and 1 year) of LV ejection fraction, diastolic function, geometry, cardiopulmonary exercise performance, and quality of life. In the sildenafil group only, at 6 months and 1 year, LV ejection fraction, early diastolic tissue Doppler velocities (E') at the mitral lateral (from 4.62 to 5.20 and 5.19 m/s) and septal (from 4.71 to 5.23 and 5.24 m/s) annuli significantly increased, whereas the ratio of early transmitral (E) to E' lateral decreased (from 13.1 to 9.8 to 9.4) (P-0.01). Changes were accompanied by a reverse remodeling of left atrial volume index (from 32.0 to 29.0 and 29.1 mL/m2; P2; P2), ventilation efficiency (ventilation to CO2 production slope), and quality of life (P

Original languageEnglish
Pages (from-to)8-17
Number of pages10
JournalCirculation: Heart Failure
Volume4
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Systolic Heart Failure
Left Ventricular Function
Stroke Volume
Placebos
Ventilation
Nitric Oxide
Heart Failure
Quality of Life
Atrial Remodeling
Cyclic GMP
Second Messenger Systems
Exercise
Sildenafil Citrate

Keywords

  • Cardiac remodeling
  • Diastolic function
  • Heart failure
  • PDE5 inhibition

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

@article{6875bc6bedfe4495af8745cda2fa91d1,
title = "PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Result of a 1-year, prospective, randomized, placebo-controlled study",
abstract = "Background-In heart failure (HF), a defective nitric oxide signaling is involved in left ventricular (LV) diastolic abnormalities and remodeling. PDE5 inhibition, by blocking degradation of nitric oxide second-messenger cyclic guanosine monophosphate, might be beneficial. In a cohort of systolic HF patients, we tested the effects of PDE5 inhibition (sildenafil) on LV ejection fraction, diastolic function, cardiac geometry, and clinical status. Methods and Results-Forty-five HF patients (New York Heart Association class II-III) were randomly assigned to placebo or sildenafil (50 mg three times per day) for 1 year, with assessment (6 months and 1 year) of LV ejection fraction, diastolic function, geometry, cardiopulmonary exercise performance, and quality of life. In the sildenafil group only, at 6 months and 1 year, LV ejection fraction, early diastolic tissue Doppler velocities (E') at the mitral lateral (from 4.62 to 5.20 and 5.19 m/s) and septal (from 4.71 to 5.23 and 5.24 m/s) annuli significantly increased, whereas the ratio of early transmitral (E) to E' lateral decreased (from 13.1 to 9.8 to 9.4) (P-0.01). Changes were accompanied by a reverse remodeling of left atrial volume index (from 32.0 to 29.0 and 29.1 mL/m2; P2; P2), ventilation efficiency (ventilation to CO2 production slope), and quality of life (P",
keywords = "Cardiac remodeling, Diastolic function, Heart failure, PDE5 inhibition",
author = "Marco Guazzi and Marco Vicenzi and Ross Arena and Guazzi, {Maurizio D.}",
year = "2011",
month = "1",
doi = "10.1161/CIRCHEARTFAILURE.110.944694",
language = "English",
volume = "4",
pages = "8--17",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure

T2 - Result of a 1-year, prospective, randomized, placebo-controlled study

AU - Guazzi, Marco

AU - Vicenzi, Marco

AU - Arena, Ross

AU - Guazzi, Maurizio D.

PY - 2011/1

Y1 - 2011/1

N2 - Background-In heart failure (HF), a defective nitric oxide signaling is involved in left ventricular (LV) diastolic abnormalities and remodeling. PDE5 inhibition, by blocking degradation of nitric oxide second-messenger cyclic guanosine monophosphate, might be beneficial. In a cohort of systolic HF patients, we tested the effects of PDE5 inhibition (sildenafil) on LV ejection fraction, diastolic function, cardiac geometry, and clinical status. Methods and Results-Forty-five HF patients (New York Heart Association class II-III) were randomly assigned to placebo or sildenafil (50 mg three times per day) for 1 year, with assessment (6 months and 1 year) of LV ejection fraction, diastolic function, geometry, cardiopulmonary exercise performance, and quality of life. In the sildenafil group only, at 6 months and 1 year, LV ejection fraction, early diastolic tissue Doppler velocities (E') at the mitral lateral (from 4.62 to 5.20 and 5.19 m/s) and septal (from 4.71 to 5.23 and 5.24 m/s) annuli significantly increased, whereas the ratio of early transmitral (E) to E' lateral decreased (from 13.1 to 9.8 to 9.4) (P-0.01). Changes were accompanied by a reverse remodeling of left atrial volume index (from 32.0 to 29.0 and 29.1 mL/m2; P2; P2), ventilation efficiency (ventilation to CO2 production slope), and quality of life (P

AB - Background-In heart failure (HF), a defective nitric oxide signaling is involved in left ventricular (LV) diastolic abnormalities and remodeling. PDE5 inhibition, by blocking degradation of nitric oxide second-messenger cyclic guanosine monophosphate, might be beneficial. In a cohort of systolic HF patients, we tested the effects of PDE5 inhibition (sildenafil) on LV ejection fraction, diastolic function, cardiac geometry, and clinical status. Methods and Results-Forty-five HF patients (New York Heart Association class II-III) were randomly assigned to placebo or sildenafil (50 mg three times per day) for 1 year, with assessment (6 months and 1 year) of LV ejection fraction, diastolic function, geometry, cardiopulmonary exercise performance, and quality of life. In the sildenafil group only, at 6 months and 1 year, LV ejection fraction, early diastolic tissue Doppler velocities (E') at the mitral lateral (from 4.62 to 5.20 and 5.19 m/s) and septal (from 4.71 to 5.23 and 5.24 m/s) annuli significantly increased, whereas the ratio of early transmitral (E) to E' lateral decreased (from 13.1 to 9.8 to 9.4) (P-0.01). Changes were accompanied by a reverse remodeling of left atrial volume index (from 32.0 to 29.0 and 29.1 mL/m2; P2; P2), ventilation efficiency (ventilation to CO2 production slope), and quality of life (P

KW - Cardiac remodeling

KW - Diastolic function

KW - Heart failure

KW - PDE5 inhibition

UR - http://www.scopus.com/inward/record.url?scp=79551580284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551580284&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.110.944694

DO - 10.1161/CIRCHEARTFAILURE.110.944694

M3 - Article

C2 - 21036891

AN - SCOPUS:79551580284

VL - 4

SP - 8

EP - 17

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 1

ER -